Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Lupus
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Lupus
    TopAbstracts in Lupus 11/23/2009 - (DGNews)
    TopAbstracts in Lupus 11/09/2009 - (DGNews)
    Recurrent Lupus Nephritis in Kidney Transplant Recipients With SLE Can Be Predicted: Presented at Renal Week 2009 - (DGDispatch)
    TopAbstracts in Lupus 10/26/2009 - (DGNews)
    Belimumab Reduces Systemic Lupus Erythematosus Disease Activity, Flares, and Prednisone Usage: Presented at ACR/ARHP - (DGDispatch)

    News archive

     Recent webcasts/CME - Lupus
      The Epidemiology of Increased Cardiovascular Death in Inflammatory Arthritis
      Systemic Lupus Erythematosus: Pathology, Diagnosis, and Treatment
      The Faces of SLE: Assessing Disease Activity, Response to Therapy, and Control of Comorbidities
      Advances in B-Cell Biology in the Treatment of Autoimmune and Inflammatory Diseases
      Neuroinflammatory Diseases in Rheumatology

      Webcasts/CME archive

       Recent cases - Lupus
        HELLP Syndrome, Multiple Liver Infarctions, and Intrauterine Fetal Death in a Patient with Systemic Lupus Erythematosus and Antiphospholipid Syndrome
        Infestation by Norwegian scabies
        Giant Coronary Aneurysm in a Patient with Systemic Lupus Erythematosus
        Multisystem Failure Due to Three Coexisting Autoimmune Diseases
        Primary Osteosarcoma of the Urinary Bladder Following Cyclophosphamide Therapy for Systemic Lupus Erythematosus: A Case Report

        Cases archive
          




        my personal edition > lupus > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Multitarget Immune Therapy Improves Outcomes of Severe Lupus Nephritis

          Washington, DC -- July 2, 2008 -- A new treatment using a combination of drugs targeting different parts of the immune system improves the recovery rate for patients with severe lupus involving the kidneys, according to a study in the Journal of the American Society of Nephrology.

          "In our study, multitarget therapy is shown to be superior to traditional therapy for inducing complete remission of class V+IV lupus nephritis, with few side effects," said lead author Lei-Shi Li, MD, Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.

          "We considered that, since the impact of severe SLE [systemic lupus erythematosus] on the kidney involves various parts of the immune system, it is necessary to treat the different immune targets with a combination of immunosuppressant drugs."

          The study included 40 patients with severe lupus nephritis (class V+IV). Patients were divided into 2 groups. The first group received the multitarget therapy, consisting of tacrolimus, mycophenolate mofetil, plus a steroid. The other group received standard, single-drug, treatment with cyclophosphamide.

          The complete remission rate, with recovery of normal kidney function, was about 4 times higher among patients receiving the 3-drug combination. "For patients receiving multitarget therapy, the complete remission rate reached 65% at 9 months, versus only 15% under traditional therapy," said Dr. Li.

          Some patients in both groups had partial remission, with some return of kidney function. Overall, 95% of patients in the multitarget therapy group had partial or complete remission, compared with 55% of patients in the single-drug therapy group. The rate of most adverse effects was also lower with multitarget therapy.

          The authors stress that their study is only preliminary. The study includes a small group of patients from a single hospital, with a relatively short follow-up time. Larger randomised trials with longer follow-up are required.

          SOURCE: American Society of Nephrology




        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send